PRO 2023

Summary:

BTAI is in a challenging situation with respect to BXCL 701 (talabostat), the oncology asset now at the heart of its immuno-oncology subsidiary, Onkosxcel because talabostat is a prior art compound not discovered by Onkosxcel or BTAI (FIG. 1).

The active ingredient in BTAI's platform in a drug, Igalmi (BXCL 501), is the drug dexmedetomidine, which has been available since 1999 and is now used for intravenous administration before intubation. It is available under the brand Precedex, which is available as a generic ( https://www.drugs.com/price-guide/precedex ). It's chemical structure is well known^1.

Already a month into 2023 but still a lot of big events coming this quarter. We have a number of readouts coming including GTHX phase 3 data in Feb  and ASCO-GU meeting mid Feb . The table below highlights catalysts coming in the next few weeks to keep an eye on. Connect with us and fellow traders in our Discord chat .

Summary

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including GTHX phase 3 data in Feb , ASCO-GU meeting  mid Feb, and lots of Alzheimer's readouts  throughout the year. The table below highlights catalysts coming in the next few weeks to keep an eye on. Connect with us & fellow traders in our Discord chat  (drop me a message that you're premium to access the premium chat channels).

Summary:

Article being drafted

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst readouts . See below for a table full of major events you should keep an eye on that are expected in the coming weeks.

First posted 1/19/2023; last updated 3/1/23

Last updated 3/1/23

Summary:

AUPH PR on settlement of patent disputes with the Indian generic company, Sun is very brief. See entire substantive portion of press release below*. Nothing more filed with SEC.